▪ Managed a value-based and innovation-focused public-private portfolio of ~60+ investments across Life Sciences and Healthcare with an AUM of $1.5B+.▪ Led idea generation, diligence, negotiations, deal structuring, syndication, and managing investments across firm’s healthcare funds.▪ Led firm's private investments in Annexon Biosciences, a pioneer in autoimmune and neurological diseases, Freeline Therapeutics, a clinical stage gene therapy company, Vectiv Bio, a clinical stage rare disease company (acquired for $1.15B), Prometheus Biosciences, a precision autoimmune disease company (acquired for $10.8B), DiCE Therapeutics, a novel small molecule autoimmune disease company (acquired for $2.4B), Cullinan Oncology, a clinical stage oncology company, BioSplice Therapeutics, a spliceosome focused clinical stage company, Arch Oncology, a clinical stage immune-oncology company, Shoreline Biosciences, an iPSC-based cell therapy company, Turnstone Biologics, a cell therapy company, Lexeo Therapeutics, a neuro and cardiac focused gene therapy company, Kojin Therapeutics, an early stage oncology company, Flare Therapeutics, an early stage transcription-factor focused oncology company, Korro Bio, an mRNA editing focused company, and Freenome, a leading liquid biopsy diagnostic company.▪ Board Director on Arch Oncology, BioSplice Therapeutics, Goldfinch Bio, Korro Bio, Prometheus Biosciences. Served on audit, science, and strategic financing and transaction committees.▪ Board Observer on DiCE Therapeutics, Lexeo Therapeutics, and Shoreline Biosciences▪ Led recruitment and training of healthcare team comprising of Ph.Ds, MDs, and CFAs.▪ Led the development of an internal data science and analytics system to assimilate variety of public and proprietary datasets including clinical, commercial, and financial data on companies to enable real-time risk-adjusted portfolio projections and optimization.

▪ Pro-actively sourced and drove investment (diligence, term sheet negotiation, syndicate building) in ViaCyte, a stem cell therapy focused company developing cures for diabetes (acquired for $320M), Annexon Biosciences, an autoimmune focused company that is developing a suite of fit-for-purpose monoclonal antibodies for several autoimmune and neurological diseases, and Pharvaris, a rare disease company developing a best-in-class oral drug for hereditary angioedema (HAE).

▪ Co-led 2 completed deals currently in portfolio. First deal was an investment in a publicly traded depression focused small molecule company. Second deal was an investment in a private company developing a monoclonal antibody for a rare debilitating dermatological indication.▪ Successfully co-led investment process through internal investment committee for 2 deals that didn't end up in portfolio due to deal dynamics.

▪ Led therapeutic area (Ophthalmology, Rare Neurological and Neuromuscular diseases) efforts to screen, evaluate, and prioritize external opportunities for collaborations, partnerships, in-licensing, and acquisitions.▪ Co-led search and evaluation of small molecule and protein/antibody identification, screening, and optimization technologies for collaborations, in-licensing, and acquisitions.▪ Co-led cross-functional due diligence teams including scientific, clinical, technical, finance, and commercial representatives to assess external technologies and products.▪ Developed and maintained relationships with key internal stakeholders including senior executives and scientists and a wide array of external industry participants including management teams of biotech companies, venture capitalists, academic institutions, and investigators, and investment bankers.

▪ Team was responsible for assessing external in-licensing and partnering opportunities and proposing deals and strategies to internal stakeholders include franchise head, disease area head, and head of development.▪ Provided scientific, technical, and strategic analyses on external opportunities. Areas of input included manufacturing, design of appropriate toxicology and pharmacology studies, intellectual property, and clinical plan to establish or confirm proof-of-concept.

Global Project Team Leader – Long-Acting Antibody and Protein Technologies▪ Defined Target Product Profile and conceived project strategy by performing competitive and technical landscape and business value analyses.▪ Expanded application and translation of technology to several indications including rheumatoid and osteoarthritis, bone regeneration, and inflammatory diseases.▪ Contributed to overall therapeutic area strategy including future market positioning and life cycle management with follow-on technologies.▪ Led a global cross-disciplinary team tasked with developing second generation technology to enable biological drugs to be dosed 1-2 times per year. In addition to providing scientific guidance, responsibilities include liaising with various line functions to develop and execute project strategy and timelines.▪ Co-developed intellectual property strategy and co-authored four patents long-acting technology platform.Co-Project Team Leader for best-in-class disease-modifying biotherapeutic for Glaucoma.▪ Team’s goal was to establish mechanism of action of novel target, establish safety and efficacy due to pathway modulation, and develop a therapeutic to lower intra-ocular pressure in Glaucoma patients.Project Team Leader – Multi-Functional Antibody Technologies▪ Led a multidisciplinary team designing and optimizing novel multi-functional (bi- and tri-specific) therapeutic proteins and antibodies.▪ Team’s goal was to establish a robust technology platform that can be widely used for combinations of various therapeutic assets.▪ Designed novel formats for multi-functional antibodies and antibody-protein fusions.

Global Project Team Leader – Half-life Extension Technology Platform▪ Selected to lead top priority project focused on developing best-in-class long-acting biologics.▪ Led team that delivered first generation long-acting molecule for first-in-human proof-of-concept studies in ~ 4 years; IND filed and approved (co-authored IND, IB, and clinical protocol). Phase I/II studies ongoing.▪ Assessed overall competitive landscape and conceived novel strategy to produce clearly differentiated best-in-class technology to support the Novartis pipeline for the next 10+ years.▪ Organized global strategy workshop between various global divisions (Research, Alcon, and Novartis Pharmaceuticals) to formulate long-acting and sustained release strategy for Ophthalmology.▪ Authored 1 patent, 1 manuscript (in process), project reviews, and technical reports for team, disease area head, various internal decision boards, and external advisory boards.Global Project Team Leader – First-in-Class Antibody for Diabetic Retinopathy and Wet AMD▪ Successfully led a multi-disciplinary team consisting of representatives from toxicology, pharmacokinetics, modeling and simulations, manufacturing, translational medicine, and patents to advance novel antibody fragment (Fab) to human clinical trials.▪ Led research team that validated target and screened > 100 antibodies to identify final 4 Fabs that achieved pre-defined success criteria in terms of affinity, potency, efficacy, safety, and manufacturability.▪ Prepared and successfully presented reports that summarized key project activities including integrated pre-clinical and clinical plans to internal decision boards.Research Team Project Leader – Proof-of-concept trial for two anti-inflammatory antibodies▪ Prepared key decision-enabling analyses of targets and unmet need to convince executive board to undertake clinical trials for highly prevalent disease with high unmet medical need.

Project Title: “Molecular mechanisms and nanotherapeutics for neurodegenerative diseases.”▪ Recruited, trained, and led a team of 3 scientists to develop novel nanotherapeutics for anemia, diabetes, Alzheimer’s disease, and Parkinson’s disease by targeting the oxidative stress pathway.▪ Established and led a cross-functional collaboration with the University of Central Florida and Lockheed Martin to screen novel nanoparticles as a counter measure against radiation sickness (NASA/DOD supported). ▪ Performed critical validation of a novel non-invasive laser-based diagnostic platform for Alzheimer’s disease.▪ Authored research grants for the Michael J Fox Foundation and National Science Foundation (~$2.5MM).▪ Collaborated to elucidate the molecular mechanisms of TDP-43 and LRRK2 in Parkinson’s disease. Work resulted in J. Neuroscience paper in <3 months.

▪ Led company’s core scientific efforts in developing a brain permeable molecule to treat Alzheimer’s disease. ▪ Performed due diligence and managed relationships with CROs for company’s pre-clinical outsourcing work.▪ Developed a library of small molecules as potential disease-modifying therapeutics for several neuroscience diseases.▪ Co-authored and leveraged company’s business and scientific operating plan and IP portfolio to evangelize local and international investors to raise >$220,000 in seed capital.▪ Negotiated exclusive license with the University of Washington Technology Transfer Office.

Project Title: “Design and development of novel peptidomimetic therapeutics for protein aggregation diseases.”▪ 6 first-author peer reviewed publications, 2 first-author peer reviewed international conference abstracts/presentations, and 1 international patent.▪ Studied the molecular mechanisms of unfolding and aggregation diseases with a special emphasis on amyloidosis.▪ Mentored 3 research assistants to successful careers in Medicine and Industry.

▪ Evaluated business plan, performed in-depth financial modeling and valuation, developed risk mitigation strategies, and performed due diligence of company and potential acquirers.▪ Deliverables used successfully by CEO to raise $2MM in Venture Capital and establish strategic alliance with Singapore Technologies for the company’s flagship product, the People Portal II, the world's first non-intrusive walk-through detector that accurately detects explosives, weapons, ceramics, and drugs on a person.